Lung metastases.

Up to 50% of patients with metastatic cancer develop lung metastases during their disease course. Lung metastases are linked to poor prognosis across various cancer types and might impair the quality of life of patients, causing dyspnoea, cough, haemoptysis and pain, potentially diminishing physical, functional and emotional well-being. Lung metastases arise from a complex interplay of tumour-secreted factors such as VEGF, TGFβ and CCL2, which drive vascular remodelling, immune cell recruitment and extracellular matrix reprogramming.

Gastric conduit necrosis following esophagectomy: is conduit salvage feasible?

Conduit necrosis (CN) typically requires operative reintervention with resection of the conduit and reconstructive surgery. We describe the outcomes of managing CN both surgically and endoscopically with a focus on conduit salvage. A retrospective, single center, cohort study of a prospectively maintained database was performed.

VALUE Trial: Phase 1 safety and feasibility study of same-day discharge after video-assisted thoracoscopic surgery lung resection.

Objectives: Although Enhanced Recovery After Surgery programs are becoming more prevalent in thoracic surgery, minimal prospective research exists for same-day discharge after lung resection. Thus, this trial aimed to evaluate the safety and feasibility of same-day discharge after video-assisted thoracoscopic surgery.

Methods: This phase 1 registered trial (NCT05583916) enrolled patients from a single institution who were candidates for a video-assisted thoracoscopic surgery anatomic or wedge resection to treat confirmed or suspected lung malignancy.

An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer.

A subset of perivascular tumor-associated macrophages (PvTAMs) expressing lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) relies on heme oxygenase-1 (HO-1) activity to maintain an immunologically cold tumor microenvironment, which suppresses the efficacy of chemotherapy. Consequently, HO-1 inhibition represents a strategy to target immunosuppressive LYVE-1 PvTAMs and improve therapeutic responses. We developed and characterized KCL-HO-1i, a small-molecule, orally bioavailable HO-1 inhibitor.

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`.

The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) ribociclib, abemaciclib, and palbociclib have transformed outcomes in patients with ER+ /HER2 - advanced breast cancer (BC). However, most patients eventually progress, and therapeutic options beyond CDK4/6i are an area of ongoing investigation. Here, we generated and evaluated ribociclib, abemaciclib, and palbociclib-resistant BCs.